On December 10, 2014, the "Research and Development Seminar on CHA Injection, a Class 1.2 Antitumor New Drug" was organized by the Institute of Materia Medica, Chinese Academy of Medical Sciences and held in Beijing. The participating experts and leaders are as follows:

Academician Sang Guowei from the National Institutes for Food and Drug Control
Academician Zhang Boli from Tianjin University of Traditional Chinese Medicine
Mr. Song Ruilin, President of the China Pharmaceutical Innovation and Promotion Association
Mr. Zhang Yongxiang, Minister of the Science and Technology Department of the Academy of Military Medical Sciences
Mr. Ji Jiafu, President of Beijing Cancer Hospital
Mr. Shao Qingxiang from the Zhejiang Academy of Medical Sciences
Mr. Chen Shilin, Director of the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences
Mr. Sun Xiaobo, Director of the Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences
Mr. Yang Shengwan, Deputy Director of the Information Center of the General Office of the National People's Congress
Mr. Mao Junfeng from the General Office of the Standing Committee of the National People's Congress
Ms. Feng Lan from the China Pharmaceutical Innovation and Promotion Association
Professor Gong Jifang from Beijing Cancer Hospital

The meeting was chaired by Dean Jiang Jiandong.

As the drug invention entity, Sichuan Jiuzhang Biotechnology Co., Ltd. participated in this meeting. Mr. Zhang Jie, the Chairman and General Manager of the company, and Mr. Huang Jun, the Director of the company's Technology R&D Department, summarized and reported on the preliminary R&D situation of the drug and the progress of the project.

Director Zhang Jinlan of the Institute of Materia Medica summarized and reported on the general situation of the preliminary application of CHA.

Chen Xiaoguang, Deputy Dean and Secretary of the Party Committee of the Institute of Materia Medica, conducted an in-depth analysis of the commonly used tumor treatment methods internationally and the current immunotherapy for tumors at home and abroad. Then, he introduced the anti-tumor mechanism of chlorogenic acid and compared CHA with the existing treatment methods.

The participating experts had a heated discussion on the chlorogenic acid project and gave full affirmation to the CHA project.